Basis: Current FMP quote-based enterprise value / four-quarter operating income. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBIT ratio is N/A as of 2026-10-06T14:06:54.426Z.
Calculation as of: 2026-10-06T14:06:54.426Z.
Quote observation: 2026-10-06T14:05:08.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 767633254d5919bd59cda52a5696942c7bb29bc9076435c5b91744fa0c767718
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBIT RATIO
N/A
Market Cap
$45.60M
EV/EBIT Ratio
N/A
TTM Avg
7.97x
3Y Avg
11.01x
5Y Avg
11.01x
Market Cap
$40.28M
EV/EBIT Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | EV/EBIT RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Werewolf Therapeutics, Inc. (HOWL) | $45.07M | N/A | N/A | N/A | N/A |
| DarioHealth Corp. (DRIO)vs › | $45.37M | N/A | 17.26x | 19.56x | 25.78x |
| BioStem Technologies, Inc. (BSEM)vs › | $45.60M | N/A | 7.97x | 11.01x | 11.01x |
| Lite Strategy, Inc. (LITS)vs › | $47.47M | N/A | N/A | N/A | N/A |
| Filana Therapeutics, Inc. (FLNA)vs › | $42.46M | N/A | N/A | N/A | N/A |
| CVRx, Inc. (CVRX)vs › | $42.19M | N/A | N/A | N/A | N/A |
| Celularity Inc. (CELU)vs › | $48.03M | N/A | N/A | N/A | N/A |
| Metagenomi, Inc. Common Stock (MGX)vs › | $40.28M | N/A | N/A | N/A | N/A |
| Clene Inc. (CLNN)vs › | $49.00M | N/A | N/A | N/A | N/A |
| Incannex Healthcare Limited (IXHL)vs › | $38.82M | N/A | N/A | N/A | N/A |
EV/EBIT = Enterprise Value / EBIT (TTM)
Enterprise value to EBIT compares total company value to operating earnings, accounting for depreciation unlike EV/EBITDA.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
